Home / News / Xifaxan And Viberzi To Give Facelift To The Global Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022 : Credence Research

Xifaxan And Viberzi To Give Facelift To The Global Irritable Bowel Syndrome With Diarrhea Drugs Market Reaching USD 221 Mn By 2022 : Credence Research

The latest market report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 1,115.06 Mn by 2022, expanding at a CAGR of 13.89% from 2016 to 2022.

Browse the full report Irritable Bowel Syndrome with Diarrhea (IBS-D) 2016–2022 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market

Market Insights

IBS affects between 10% to 20% individuals in the developed countries. Since the underlying cause of IBD remains unknown, the treatment market for the same is observed to be unvisited and is characterized by very few indicated drugs. By far, alosetron has been the only drug approved for IBS-D treatment. With the approval for eluxadoline (Viberzi) and rifaximin (Xifaxan), new avenues in the IBS-D treatment market have opened, giving hopes to the patients.

Both Viberzi and Xifaxan are determined to be safe, Viberzi may receive controlled substance label due to risk of potential abuse. Viberzi and other IBS-D drugs act on opioid receptors, thus it is a mu receptor antagonist and kappa receptor antagonist. On the other hand, Xifaxan is viewed as a curative regimen, since it acts by altering the bacterial flora in the guts.

Browse the full report Irritable Bowel Syndrome with Diarrhea (IBS-D) 2016–2022 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market

Xifaxan has been reportedly prescribed off label for treating IBS-D. Its formal sanction will thus support the growth in demand for the drug in the forecast period. Xifaxan is prescribed for a 14 day, thrice a day dosage; with a further additional 1 week dosage if the need arises. However, its long term role in efficiently containing IBS-D is still questioned. Viberzi, on the other hand, easily fits the profile of everyday medication for chronic disease treatment, similar to diabetes and CVD treatments. Further safety and effective assessments on these drugs are lined up, which will clear the market status of the two drugs.

The market for Viberzi is expected to cross USD 6 Mn mark by 2022, whereas Xifaxan market is expected to progress at a CAGR of moderate 4.46% during 2016-2022. IBS-D affects over 15 million Americans, with no single drugs having a clear domination in the market. Loperamide, angidepressants, alosetron, bile acid binders and similar such drugs were the standard treatments in the past. Medical professionals have largely relied on trial and error approach for treating IBS-D patients.

Latest Reports:

Angina Pectoris Treatment Market By Drug Type (Antiplatelet agents, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting Nitroglycerines, Angiotensin-converting enzyme inhibitors, Anti-ischemic agents) – Growth, Share, Opportunities & Competitive Analysis, 2015 – 2022

Drug Delivery Technologies Market By Application (Oral, Pulmonary, Transdermal, Injectable, Nasal, Implantable & Others) – Growth, Share, Opportunities & Competitive Analysis, 2015 – 2022

In-Vitro Diagnostics (IVD) Market By Products (Reagents, Instruments, Software And Services), By Techniques (Clinical Chemistry, Immunochemistry/Immunoassays, Hematology, Coagulation And Hemostasis, Microbiology, Molecular Diagnostics (MDX)), By Test Locations (Point-Of-Care Testing, Central Lab Testing, OTC/Self Testing) – Growth, Share, Opportunities & Competitive Analysis, 2015 -2022

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

What we do

We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.

No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.

Contact:

Name: Chris Smith

Designation: Global Sales Manager

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web:  Credence Research

 

Release ID: 2584

About Chris Smith

Check Also

400-400

Worldwide Survey: Contraceptives Sales Market 2016 to 2022 Size, Share, analysis,Trends and Forecast By Acute Market Reports

Report Description: Notes: Sales, means the sales volume of Contraceptives Revenue, means the sales value ...